Mini-review - Second hematopoietic stem cell transplantation for the treatment of graft failure, graft rejection or relapse after allogeneic transplantation

被引:111
作者
Wolff, SN [1 ]
机构
[1] Aastrom Biosci Inc, Ann Arbor, MI 48106 USA
关键词
graft failure; graft rejection; second HSC transplant;
D O I
10.1038/sj.bmt.1703389
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
Failure to engraft after hematopoietic stem cell transplantation (graft dysfunction) or to sustain engraftment (graft rejection) is a formidable complication due to many possible factors. These include inadequate stem cell numbers, infections, graft-versus-host disease and immunological mediated processes. Fortunately, this complication is uncommon and can be overcome by additional hematopoietic stem cell infusions. Multiple treatment alternatives have been explored including hematopoietic growth factors, additional infusions of stem cells alone, with augmented immunosuppression or with additional cytotoxic therapy. Various sources of the additional stem cells are feasible including the original donor, using another donor, using stem cells collected from the marrow or after cytokine mobilization from the peripheral blood. This report will overview this complication and review the various studies that have attempted to define both cause and therapy. However, a lack of well-designed prospective studies has made definitive recommendations difficult although basic principles have been established.
引用
收藏
页码:545 / 552
页数:8
相关论文
共 97 条
[71]  
QUINONES RR, 1993, AM J PEDIAT HEMATOL, V15, P3
[72]   Tolerance induction by "megadose" hematopoietic transplants - Donor-type human CD34 stem cells induce potent specific reduction of host anti-donor cytotoxic T lymphocyte precursors in mixed lymphocyte culture [J].
Rachamim, N ;
Gan, J ;
Segall, H ;
Krauthgamer, R ;
Marcus, H ;
Berrebi, A ;
Martelli, M ;
Reisner, Y .
TRANSPLANTATION, 1998, 65 (10) :1386-1393
[73]  
Raddatz G, 1998, IMMUNOLOGY, V94, P101
[74]   2ND ALLOGENEIC MARROW TRANSPLANTATION FOR PATIENTS WITH RECURRENT LEUKEMIA AFTER INITIAL TRANSPLANT WITH TOTAL-BODY IRRADIATION-CONTAINING REGIMENS [J].
RADICH, JP ;
SANDERS, JE ;
BUCKNER, CD ;
MARTIN, PJ ;
PETERSEN, FB ;
BENSINGER, W ;
MCDONALD, GB ;
MORI, M ;
SCHOCH, G ;
HANSEN, JA .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (02) :304-313
[75]   Transplantation tolerance induced by "mega dose" CD34+ cell transplants [J].
Reisner, Y ;
Martelli, MF .
EXPERIMENTAL HEMATOLOGY, 2000, 28 (02) :119-127
[76]   Booster marrow or blood cells for graft failure after allogeneic bone marrow transplantation [J].
Remberger, M ;
Ringdén, O ;
Ljungman, P ;
Hägglund, H ;
Winiarski, J ;
Lönnqvist, B ;
Aschan, J .
BONE MARROW TRANSPLANTATION, 1998, 22 (01) :73-78
[77]   Allogeneic bone marrow transplant or second autograft in patients with acute leukemia who relapse after an autograft [J].
Ringdén, O ;
Labopin, M ;
Frassoni, F ;
Sanz, GF ;
Demeocq, F ;
Prentice, HG ;
Cahn, JY ;
Barbui, T ;
Meloni, G ;
Schaefer, UW ;
Reiffers, J ;
Gorin, NC .
BONE MARROW TRANSPLANTATION, 1999, 24 (04) :389-396
[78]  
ROSENFELD CS, 1995, EXP HEMATOL, V23, P626
[79]  
Russell JA, 1996, BONE MARROW TRANSPL, V18, P501
[80]   CD34+-enriched donor lymphocyte infusions in a case of pure red cell aplasia and late graft failure after major ABO-incompatible bone marrow transplantation [J].
Selleri, C ;
Raiola, A ;
De Rosa, G ;
Luciano, L ;
Pezzullo, L ;
Picardi, M ;
Rotoli, B .
BONE MARROW TRANSPLANTATION, 1998, 22 (06) :605-607